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Abstract
The increased reliability and efficiency of the quantitative polymerase chain reaction (qPCR) makes it a promising tool for
performing large-scale screening for infectious disease among high-risk individuals. To date, no study has evaluated the
specificity and sensitivity of different qPCR assays for leprosy diagnosis using a range of clinical samples that could bias
molecular results such as difficult-to-diagnose cases. In this study, qPCR assays amplifying different M. leprae gene targets,
sodA, 16S rRNA, RLEP and Ag 85B were compared for leprosy differential diagnosis. qPCR assays were performed on frozen
skin biopsy samples from a total of 62 patients: 21 untreated multibacillary (MB), 26 untreated paucibacillary (PB) leprosy
patients, as well as 10 patients suffering from other dermatological diseases and 5 healthy donors. To develop standardized
protocols and to overcome the bias resulted from using chromosome count cutoffs arbitrarily defined for different assays,
decision tree classifiers were used to estimate optimum cutoffs and to evaluate the assays. As a result, we found a
decreasing sensitivity for Ag 85B (66.1%), 16S rRNA (62.9%), and sodA (59.7%) optimized assay classifiers, but with similar
maximum specificity for leprosy diagnosis. Conversely, the RLEP assay showed to be the most sensitive (87.1%). Moreover,
RLEP assay was positive for 3 samples of patients originally not diagnosed as having leprosy, but these patients developed
leprosy 5–10 years after the collection of the biopsy. In addition, 4 other samples of patients clinically classified as non-
leprosy presented detectable chromosome counts in their samples by the RLEP assay suggesting that those patients either
had leprosy that was misdiagnosed or a subclinical state of leprosy. Overall, these results are encouraging and suggest that
RLEP assay could be useful as a sensitive diagnostic test to detect M. leprae infection before major clinical manifestations.
Citation: Martinez AN, Ribeiro-Alves M, Sarno EN, Moraes MO (2011) Evaluation of qPCR-Based Assays for Leprosy Diagnosis Directly in Clinical Specimens. PLoS
Negl Trop Dis 5(10): e1354. doi:10.1371/journal.pntd.0001354
Editor: Mehmet Ali Ozcel, Ege University, Turkey
Received May 5, 2011; Accepted August 26, 2011; Published October 11, 2011
Copyright:  2011 Martinez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by FAPERJ (Fundac ¸a ˜o de Amparo a Pesquisa do Estado do Rio de Janeiro), CAPES (Coordenac ¸a ˜o de Aperfeic ¸oamento de
Pessoal de Nı ´vel Superior), and CNPq (Conselho Nacional de Desenvolvimento Cientı ´fico e Tecnolo ´gico) and FIOCRUZ (Fundac ¸a ˜o Oswaldo Cruz). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mmoraes@fiocruz.br
. These authors contributed equally to this work.
Introduction
Leprosy is a slowly progressive spectral disease caused by
Mycobacterium leprae, an intracellular bacterium that has a tropism
for macrophages in skin and Schwann cells in peripheral nerves. In
1966, Ridley and Jopling classified a five forms spectrum disease
that at one end of the spectrum is tuberculoid (TT) leprosy, where
patients mount a strong cell-mediated immune response against
M. leprae resulting in the reduction and eventual clearance of the
infecting bacteria. At the other end is the lepromatous (LL), a
condition characterized by highly infected and disseminated skin
lesions with high levels of anti-M. leprae antibodies in serum and a
weak cell-mediated immune response towards M. leprae antigens
[1,2]. In between these two polar forms, unstable borderline cases
with specific clinical, immunological and pathological character-
istics exist and are subdivided into borderline tuberculoid (BT),
borderline borderline (BB) and borderline lepromatous (BL). In
addition, among bacterial pathogens, infection of peripheral
nerves is a unique property of M. leprae and patients can exhibit
a rare form known as pure neural leprosy, PNL [3]. Moreover,
very early skin lesions may be presented as relatively nonspecific
perineural infiltrates in which rare acid-fast bacilli can be detected,
but without sufficient infiltrates to classify them; these are called
indeterminate (I). The disease is challenging to diagnose since
there is no gold standard method to detect M. leprae or its cell
components (DNA, lipids or proteins). The major difficulty in
leprosy diagnosis concerns tuberculoid, indeterminate or PNL
forms where acid-fast bacilli (AFB) in slit smears are very rare or
absent.
Historically, one of the limitations to develop new diagnostic
tests was the inability to grow M. leprae in vitro. Animal models such
as mouse footpad [4] and armadillos [5] helped to overcome this
problem and aided improvements in leprosy research. Since then,
a wave of significant progress in understanding the molecular
structure of M. leprae has been achieved including the completion
of the genome sequencing of the leprosy bacillus [6]. Given that,
simple and specific PCR assays for detection of small numbers of
bacteria in clinical samples have been proposed. During the past
20 years, PCR methods have been developed to amplify different
gene targets of M. leprae. These include genes encoding various
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antigen [8], or the 65-kDa antigen [9], Ag 85B [10], 16S rRNA
[11] and the repetitive sequences (RLEP) [12]. Recently,
quantitative PCR (qPCR) assays which are based on real-time
quantitative fluorescence detection are replacing conventional
end-point PCR in many laboratories. They have improved
specificity and sensitivity for quantification of bacterial DNA or
cDNA content directly in clinical samples, in addition to more
rapid turnaround time, which surpasses the conventional PCR
technique using gel or colorimetric detection sensitivity [10–13].
In fact, as much as 40–50% of cases missed by standard
histology and other clinical or laboratory methods can be
confirmed by the use of conventional molecular methods, and
one would speculate whether qPCR would improve this rate of
diagnosis [14]. However, also to be considered is the fact that
PCR-based diagnosis has a considerable level of failure in
confirmed leprosy cases after clinical or laboratory standards.
This is probably due to variability of clinical forms, i.e. the reduced
amounts of M. leprae among paucibacillary patients reflect the need
to further optimize molecular methods. The performance of PCR
assays for M. leprae detection, however, has only been evaluated
through comparative studies: comparing two different gene targets
[15] or reproduction of standardized PCR assays by few groups
[8,10,11,13]. Hence, standardization of the PCR assays for quality
assurance of leprosy diagnosis is still lacking. Identification and
establishment of standardized procedures to provide adequate
clinical material, nucleic acid extraction protocol, primer target,
amplicon size, PCR inhibition and control of amplicon contam-
ination, fluorescence threshold determination, standard curve
quality control, and estimated chromosome counts cutoffs will
assure a more reliable and reproducible diagnosis of the disease.
Assays with standardized procedures can be also of immense help
for others dermatological differential diagnosis, for instance,
leishmaniasis, cutaneous tuberculosis, sarcoidosis, where patho-
logical examination is inconclusive.
In the present study, we have developed and evaluated decision
tree classifiers [16] from absolute chromosome count estimates
based on standard curves built from qPCR assays for leprosy
diagnosis, which account for biological and clinical heterogeneity
(TT vs LL). Four previously described TaqManH qPCR assays
were compared for the identification of M. leprae in 62 skin biopsies
from patients diagnosed with leprosy, skin biopsies from patients
initially suspect of having leprosy, or healthy skin of non-leprosy
subjects. The comparisons were made based on the following gene
targets: Ag 85B [10], sodA and 16S rRNA [12] and RLEP [13] and
a confirmatory diagnosis from patients previously diagnosed by a
committee of experts (pathologists and dermatologists) based on
clinical and laboratorial tests at the outpatient unit of the Oswaldo
Cruz Institute, Fiocruz. We intentionally include a higher
proportion of paucibacillary samples, especially the cases where
rarely M. leprae (DNA or bacilli) is detected. These cases
correspond to the indeterminate, pure neural and tuberculoid
forms, i.e., exactly when the leprosy diagnosis is more challenging.
Thus, the intent here was to identify and select the most sensitive
and specific PCR assay useful for differential and early diagnosis of
leprosy.
Materials and Methods
Objectives
The main goal of this study was to comparatively evaluate four
different TaqManH qPCR assays for leprosy diagnosis using a
range of clinical samples that could bias the results. To develop
standardized protocols and to overcome the bias resulted from
arbitrarily analysis of the assays, we propose the use of decision
tree classifiers to estimate optimum cutoffs. The following gene
targets were used to determine the presence and levels of M. leprae:
Ag 85A, sodA and 16S rRNA and RLEP.
Collection and processing of clinical material
Punch skin biopsy (6 mm
3) specimens from patients were
obtained at the outpatient unit of the Oswaldo Cruz Institute,
Fiocruz, Rio de Janeiro, Brazil. The patients were classified
clinically, bacteriologically, and histopathologically, according to
the Ridley-Jopling scale (R&J) [1]. A total of 62 skin biopsies were
included in this study (Table 1 and Table S1). Multibacillary (MB)
patients (LL, BL and BB) had bacteriological indexes (BI) ranging
from +1t o+5.5 while all paucibacillary (PB) patients (including
BT, I, and PNL forms) had negative BI. The logarithmic index of
bacilli in the biopsy (LBI) [17] of MB patients was also evaluated
and ranged from 1 to 6. Ten skin biopsy specimens from
individuals that had suspicion of leprosy, but were further
evaluated and clinically diagnosed with other skin diseases and
five biopsies from normal healthy skin were also included as
Table 1. Summary description of skin biopsy specimens used
in the study.
Patients
Number of
skin biopsies Clinical Forms*
PB MB
I PNL TT BT BB BL LL
Non leprosy 1 5 - - -----
leprosy 47 12 1 2 11 5 5 11
*according to the Ridley and Jopling classification. PB-paucibacillary, MB-
multibacillary, I-indeterminate, PNL – pure neural leprosy, TT- tuberculoid, BT-
borderline tuberculoid, BB- borderline; BL- borderline lepromatous; LL-
lepromatous.
doi:10.1371/journal.pntd.0001354.t001
Author Summary
Leprosy is a chronic infectious disease caused by
Mycobacterium leprae an obligate intracellular pathogen
that can infect cells in skin and nerves. Leprosy still affects
211,903 individuals per year worldwide and lead to
permanent nerve injury that is generally associated with
late diagnosis. The mechanisms of interaction between
pathogen and the human host that leads to active disease
are complex and there is no gold standard to detect M.
leprae or host response that could early identify patients
preventing severe forms of the disease, extensive nerve
damage and disabilities. Thus, diagnosis relies mainly on
clinical parameters and histopathological and bacteriolog-
ical sometimes help to ascertain clinical form of patients.
But, recently, advances in the genome of the pathogen
provided extended information towards new targets to
design novel genetic or immunological markers. Also novel
molecular biology methods exhibiting higher sensitivity
along with easy to handle apparatus based on nucleic acid
detection are available. Here, we test and compare
different assays for quantitative PCR (qPCR) designed to
amplify specific M. leprae targets enriching the test sample
with difficult-to-diagnose leprosy cases. Our results sug-
gest that qPCR specially the one targeting repetitive
element (RLEP) could be used to early detection of leprosy
cases.
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individuals participating in this study were informed of the
purpose of the study, and written consent was obtained from all
participants. The study was approved by the FIOCRUZ Ethical
Committee.
DNA extraction from skin biopsy specimens
DNA was extracted from half of the 6 mm
3 skin biopsy
specimens using proteinase K digestion as described elsewhere
[10] with modifications. Briefly, biopsy specimens were thawed at
room temperature, minced and digested for 12 h at 60uC with
proteinase K (300 mg/ml) in 100 mM Tris-HCl (pH 7.4),
150 mM NaCl, and 10 mM EDTA (pH 8.0). In order to help
break M. leprae cell wall, biopsy samples were then added to
FastRNAH Blue tubes and homogenized twice in the FastPrepH FP
24 instrument (Qbiogene, Carlsbad, CA, USA) at a speed setting
of 6.5 for 45 sec62 with 5 min rest between homogenizations.
The homogenates were extracted with phenol:chloroform:isoamyl
alcohol. DNA was precipitated with isopropanol, washed in 70%
ethanol, dried at room temperature, and resuspended in
approximately 30 ml RNase Free H2O.
Quantitative Polimerase Chain Reaction (qPCR)
The levels of M. leprae Ag 85B [10], sodA [12], 16S rRNA [12],
and RLEP [13] in skin biopsy specimens were estimated using
TaqManH qPCR amplification. Purified total DNA (200 ng) in
2 ml were added to a total PCR reaction volume of 25 ml
containing TaqManH 26master mix, 500 nM of each primer and
100 nM of each probe for sodA or 16S rRNA PCR assays, 200 nM
of each primer and 100 nM of the probe for RLEP PCR assay or
300 nM each primer and 100 nM probe for 85B PCR assay.
Reaction mixtures were prepared in duplicates and subjected to
50uC for 2 min, 95uC for 10 min, and 40 cycles of 95uC for 15 sec
and 60uC for 1 min using a 7000 real-time PCR system (Applied
BioSystems, Carlsbad, CA, USA). Fluorescent accumulation data
for skin biopsies specimens were analyzed by the ABI PRISM
7000 Sequence Detection System software (Applied Biosystems,
Carlsbad, CA, USA), and DRn values extracted. Cycle threshold
(Ct) determination from DRn data was conducted in the open
source software R version 2.9.1 (available at http://www.R-
project.org/).
Standard curves for qPCR assays
Standard curves were generated for each qPCR assay using five
titration curves with 10-fold dilutions of purified M. leprae DNA
from nude mouse footpads (kindly provided by Dr. Phillip Suffys)
with doses ranging from 1 ng to 10 fg. Fluorescent accumulation
data for titration curves and were analyzed by the ABI PRISM
7000 Sequence Detection System software (Applied BioAssays,
Carlsbad, CA, USA), and DRn values extracted. Cycle threshold
(Ct) determination from DRn data was also conducted in the open
source software R version 2.9.1. Ct values were plotted against
input log-doses (base 10) and standard curves determined by a
linear regression, and the coefficient of determination (R
2) used as
quality control. Then, the fitted standard curves were used to
estimate M. leprae chromosome counts for skin biopsies specimens,
considering one M. leprae genome to be equivalent to 3 fg [12].
Decision Trees building and evaluation
Classification trees for this project used the open source software
R version 2.9.1 implementation of the Quinlan’s C4.5 algorithm
[16] available in the packages ‘rpart’ and ‘caret’ (available at
http://cran.r-project.org/web/packages/), for training and eval-
uation, respectively. Decision tree classifiers were trained with the
set of estimated M. leprae chromosome counts derived from
standard curves from the four different TaqManH qPCR
diagnostic assays previously described, and classes were assigned
as C1 and C2 indicating that the skin biopsy specimen belongs to a
confirmed leprosy patient or to a non-leprosy patient, respectively.
Training parameters included: (1) prior probabilities for classes C1
and C2 equals 0.5; (2) 20, as the minimum number of observations
that must exist in a node, in order for a split to be attempted; (3)
10, as the minimum number of observations in any terminal leaf
node; and (4) Gini impurity as a measure of how often a randomly
chosen element from the set would be incorrectly labeled if it were
randomly labeled according to the distribution of labels in the
subset. A series of 5 tree classifiers were built with different
compositions of the input data. Four classifiers were built with
single attributes, given by the chromosome counts from each
diagnosis assay, while the fifth tree were built with all 4 attributes
available, and then pruned in order to minimize the expected 10-
fold cross-validation prediction accuracy. Pruning included a
complexity parameter of 0.05, informing the program that any
split which does not improve the fit by 0.05 will likely be pruned
off by cross-validation, and that hence the algorithm need not
pursue it. Also, performances of the built tree classifier were
estimated by its specificity, sensitivity, and by the trapezoidal
approximation of the area under the receiver operating charac-
teristic (ROC) curve (AUC), a graphical plot of the sensitivity, or
true positive rate (sensitivity), vs. false positive rate (12specificity),
for the decision tree classifier as its discrimination cutoffs were
varied. AUC can be seen as a measure of commitment between
sensitivity and specificity. R code is available under request to
authors.
Results
Building of qPCR assays for leprosy diagnosis in clinical
samples
Standard curves were built from the linear regression of Ct value
estimates from five titration curves with replication with 10-fold
dilutions of purified M. leprae DNA ranging from 1 ng to 10 fg for
each qPCR assay (Table 2; Figure 1). Quality control was
guaranteed by the high coefficient of determination values
achieved, ranging from 98.2% to 99.7% (Figure 1). Moreover,
to control any possible PCR inhibition, TaqManH qPCR targeting
the human TNF gene was also performed and all samples tested
positive (data not shown) indicating no inhibition. Optimal
fluorescence thresholds were chosen based on the common
practice that it should be positioned on the lower half of the
fluorescence accumulation curves plot from the 10-fold dilutions
and was used both to calculate the cycle thresholds (Ct) for
standard curves fitting and to calculate Ct for a total of 62 skin
biopsy samples, 47 from untreated leprosy patients and 15 from
patients suffering from other dermatological diseases and healthy
donors. Considering the relation of one M. leprae genome at each
3 fg dilution [10], doses estimated for each skin biopsies specimen
from all qPCR assays were converted to chromosome counts and
used as input to train classification trees for optimization of qPCR
specific chromosome counts cutoffs used in leprosy diagnosis
(Figure 2). The classification trees were also used to estimate
generalized errors that should be expected when using these qPCR
assays for leprosy diagnosis in unforeseen samples, not used in tree
fitting. These generalized errors were estimated by the 10-fold
cross-validation prediction accuracy (10-fAcc.), where data is
partitioned in 10 parts according to the original class distribution
and at each run 9 parts are used for training and one part is used
qPCR in Leprosy Diagnosis
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using M.leprae DNA for each qPCR assay was performed.
doi:10.1371/journal.pntd.0001354.g001
Table 2. Standard curves parameters and results for qPCR assays of M. leprae DNA.
Assay Fluorescence Threshold
[1] Linear Coefficients
[2]
R
2[3] Amplification
Slope Intercept Efficiency
RLEP 0.075 23.17 16.78 0.99 2.07
16S rRNA 0.161 23.15 24.99 1 2.08
Soda 0.229 23.36 25.13 0.99 1.98
Ag 85B 0.143 23.13 23.04 1 2.09
[1]Fluorescence values used as threshold for determining Ct values;
[2]Linear coefficients from a line: y=a+bx+e, where a is the intercept, b is the slope and e is the fitting error;
[3]Standard curves coefficient of determination.
doi:10.1371/journal.pntd.0001354.t002
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after the end of the 10 independent runs. Besides the 10-fAcc., we
also report specificity, clinical sensitivity and the AUC for each of
the four qPCR assays (Table 3).
Evaluation of qPCR assays for leprosy diagnosis in clinical
samples
Based on the standard curves for the four assays, using Ct values
obtained from 62 skin biopsy samples using the same fluorescence
thresholds (Tables 2 and 4), we estimated the chromosome counts
for each sample. Patients and control groups were classified
according to clinical, bacteriological and histopathological criteria
by experienced dermatologists and pathologists. Patients’ names
from other dermatological diseases were searched at disease
surveillance and control database of Brazilian publicly-funded
health care system, SUS (Portuguese for Unified Health System).
Indeed, three out of seven patients initially classified as controls
had a confirmation of leprosy after databank search (5–10 years
after biopsy collection). Therefore, those patients were reanalyzed
histologically and reclassified according to R&J and then, both
chromosome counts and diagnostic labels were used in the
evaluation of four different qPCR assays for leprosy diagnosis. We
found the estimated chromosome counts for each assay to be in
agreement with Ridley and Jopling scale for MB leprosy forms
(Figure S1). As a result of the evaluation, similar specificity and
sensitivity were found for all four assays with RLEP assay being
more sensitive (Table 3), with optimum chromosome counts
cutoffs for leprosy diagnosis estimated as greater than or equal to
0.01, 14.36, 23.79 and 0.49 for RLEP, 16S rRNA, sodA and Ag
85B, respectively. The fact that the expected mean classification
accuracy in distinguishing leprosy patients from non-leprosy with
different qPCR assays ranges from 59.7 to 87.1% is not surprising
due to the very low number of bacilli expected in I and BT
(negative BI patients) cases, which comprised 55.31% (26/47) of
leprosy samples in the dataset. As a result, since the highest
proportions of the leprosy cases belonged to indeterminate
(25.53%; 12/47), borderline tuberculoid (23.4%; 11/47), in
addition to tuberculoid (TT) and pure neural, i.e. PNL,
(27.65%; 13/47) forms (Table 1; Table S1), prediction of patients
was expected to be extremely difficult. However, this is more in
accordance to the challenging leprosy diagnostics found in day-to-
day practice of a typical outpatient unit, which is also in
accordance with our aim to validate M. leprae DNA detection
toward the situations where PCR could be really useful. These
results show that TaqManH qPCR targeting the multicopy RLEP
Figure 2. Classification trees partitions based on M. leprae chromosome counts. qPCR for 16S rRNA, 85B, RLEP and sodA assays into leprosy
(L) or non-leprosy (NL) diagnosis. We have found different optimum chromosome count (genome counts) cutoffs for predicting leprosy,
approximately greater than or equal to 14.36, 0.49, 0.01 and 23.79, respectively.
doi:10.1371/journal.pntd.0001354.g002
Table 3. Summary of the results of the decision tree classifier
for leprosy diagnosis.
Assay
Mean 10-fAcc.
(CI 95%)
[1] Sensitivity Specificity AUC
[2]
RLEP 0.871 [0.762, 0.943] 0.915 0.733 0.824
16S rRNA 0.629 [0.497, 0.748] 0.511 1 0.756
sodA 0.597 [0.464, 0.720] 0.468 1 0.734
Ag 85B 0.661 [0.530, 0.777] 0.553 1 0.777
All 0.871 [0.762, 0.943] 0.915 0.733 0.824
[1]Mean 10-fold cross-validation accuracy with 95% confidence interval;
[2]Approximate area under ROC curve.
doi:10.1371/journal.pntd.0001354.t003
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assays tested, which in turn have comparable detection, for
assessing clinical samples. In addition, the RLEP qPCR assay
proved to be more sensitive than others assays and has also a larger
approximated area under ROC curve (Table 3), which shows a
better commitment between sensitivity and specificity for this
assay. Moreover, the performance of the classifier trained with the
chromosome count estimated by all 4 assays did not improve the
ability to correctly distinguish leprosy patients with that of the
RLEP qPCR assay alone (Table 3).
Discussion
This is the first systematic PCR comparative evaluation using
different real-time assays for detection of M. leprae DNA in skin
biopsies from patients of different clinical forms of leprosy as well
as non-leprosy dermatological diseases and healthy individuals.
Our previous work [10] indicated that Ag 85B assay was specific as
it did not amplify any DNA in healthy skin biopsies. In fact, none
of the assays used in this study have shown amplification for
healthy individuals. The introduction in this study of patients who
had suspicion of leprosy like chronic dermatitis, capillaritis,
cutaneous mucinosis, bacterial erythema, leukocytoclastic vascu-
litis and folliculitis increased the complexity of the differential
diagnosis, which justifies the lower estimated sensitivities found as
compared to previous studies [10,15,18,19]. Four samples
classified as leprosy by RLEP assay presented detectable
chromosome counts ranging from 0.04 to 3.16. These putative
false positive results have to be interpreted very carefully as those
patients had a previous suspicion of leprosy. Recently, Goulart and
colleagues [20] described that among all nucleic acid markers for
leprosy diagnosis in the literature, three presented higher
sensitivity and specificity (RLEP, Ag 85B and 16S rRNA). Indeed,
our results demonstrated that RLEP qPCR assay could be used to
improve patient detection due to its high sensitivity/confidence
(100/88.9% for MB patients and 84.6/80.5% for PB patients),
although the specificity of 73.3% has to be taken into
consideration. As stated before, it is possible that the four patients
clinically and histologically classified as non-leprosy had in fact
leprosy that was misdiagnosed at the time or even a subclinical
state of leprosy, especially because the area in Rio de Janeiro,
where those people were diagnosed, is highly endemic. It is
common to observe a very long incubation period to leprosy
outcome and subclinical stages with dormant M.leprae within
granulomas are likely to occur [21]. Nevertheless, those patients
were followed up for up to 10 years and did not develop the
disease. Thus, PCR positivity might indeed represent carriage of
bacilli or subclinical infection, which does not indicate by itself the
evolution towards the disease. An opposite speculation is that the
repetitive sequence (RLEP) is highly conserved and as a result,
many homologous sequences may be present in other environ-
mental Mycobacterium species that have not been thoroughly
investigated, generating false positive results, as reported for the
M. tuberculosis IS6110 marker elsewhere [22,23]. If this last
hypothesis is true, then the use of a single copy gene such as the
Ag 85B is favored and seems to be a more promising candidate for
PCR-based diagnosis since it presented the highest confidence
(55.3%) considering the PB patients as well and compared to all
three others qPCR assays and 100% specificity.
It is feasible that the two most challenge features when
implementing a diagnostic assay based on qPCR by absolute
quantification are: the choices of the chromosome count cutoff and
its generalization error, or the accuracy of the assay for classifying a
new sample. In this study, these challenges were solved by using
decision tree classifiers. As result, in different qPCR assays
evaluated, namely RLEP, Ag 85B, sodA and 16S rRNA, we have
found different optimum chromosome count cutoffs for predicting
leprosy, approximately greater than or equal to 0.01, 0.49, 23.79
and 14.36, respectively (Figure 1; Table S1). Not surprisingly, assays
with higher chromosome count cutoffs had lower sensitivity than
thosewithlowercutoff,butwithadecreaseinitsspecificity(Table3),
which, in turn, indicates an adequate classification fit to the training
data. Also, assays with lower chromosome count cutoffs had lower
generalization error (10-fAcc.; Table 3), and so have a higher
confidence while predicting leprosy in undetermined samples.
The use of any classification assay has limitations, especially
those that oversimplify a complex disease such as leprosy. In the
absence of commonly accepted reference procedures the choice of
data processing is currently at the discretion of the researcher.
Also, since there is a shortage of publications discussing the
comparison of different DNA-based PCR assays for the detection
and enumeration of M. leprae this study provides a comparison of
four qPCR assays previously standardized and published in the
literature. Notwithstanding, an external quality assurance study on
diagnostic proficiency, which includes certifying and publishing
the results in a comparative and anonymous manner for leprosy
research would be ideal. A multicenter study with blinded samples
is essential.
Table 4. PCR positivity for different real-time PCR assays.
Clinical Form
Total number of
biopsies sodA(%) positivity 16S (%) positivity RLEP (%) positivity 85B (%) positivity
BB 5 4 (80) 5 (100) 5 (100) 5 (100)
BL 5 5 (100) 5 (100) 5 (100) 5 (100)
LL 11 11 (100) 11 (100) 11 (100) 10 (90.9)
BT 11
[a] 2 (18.2) 2 (18.2) 6 (54.5) 4 (36.4)
I 12
[b] 0 1 (8.3) 9 (75) 2 (16.7)
NP/TT 3 0 0 2 (66.7) 0
Skin from healthy donor 50000
Other dermatological
diseases
1 0 0040
[a],[b]1 BT (borderline tuberculoid) and 2 I (indeterminate) patients were initially classified as controls but confirmation of leprosy was done only after databank search
(5–10 years after biopsy collection). Then, biopsies were reanalyzed histologically and also reclassified as patients according to R&J classification.
doi:10.1371/journal.pntd.0001354.t004
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glycolipid I (PGL-I) IgM antibodies, are non-invasive and useful as
an additional aid in diagnosis [24,25]. The presence of anti-PGL-I
antibodies is known to correlate with the bacterial load [26], and
thus offers a further refinement of the WHO classification into
patients with high and low bacterial loads. However, PCR has
been proven to be more sensitive than serological tests, especially
in paucibacillary patients [25,27]. Also, due to the complex and
varying immune responses that characterize leprosy spectrum,
improved serological tests are hard to achieve and still needed.
Hence, even though serological tests may have epidemiological
relevance, the higher sensitivity of the PCR technique makes it a
more robust tool for leprosy diagnosis. Obviously, that it should be
taken into consideration that introduction of qPCR in routine
diagnosis of leprosy is not easy since it is an expensive and
laborious technique. But, it is likely that qPCR will become
cheaper and soon surpass the conventional technique by becoming
the gold standard laboratory test for leprosy diagnosis.
In tuberculosis, assays based on genexpert technology are
currently in use for detection of active disease and resistance [28].
In leprosy, a rapid and early diagnostic tool, possibly based on
qPCR, is still needed. The histopathologic and immunologic
features of indeterminate cases suggest that it is an early form of
the disease. Surprisingly, RLEP PCR assay correctly identified
75% of those patients suggesting that this can be used as a sensitive
diagnostic test to detect M. leprae infection before major clinical
manifestations. Recently, Banarjee and coworkers [29] presented
that the use of PCR positivity in a follow-up of patients’ contacts
could predict the outcome of leprosy in 20% of the individuals
suggesting that a qPCR would help detect and quantify M. leprae in
these patients indicating chemoprophylaxis of contacts when
needed. Hence, we believe that quantitation of M. leprae bacterial
loads using RLEP qPCR will contribute to understanding
mechanisms as well as being clinically important in targeting
follow-up of high risk individuals and in the development of
strategies for early detection and prevention.
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